Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.57
-0.0200-0.44%
Volume:1.41M
Turnover:6.47M
Market Cap:1.25B
PE:-13.60
High:4.70
Open:4.70
Low:4.53
Close:4.59
52wk High:6.02
52wk Low:1.05
Shares:273.92M
Float Shares:184.00M
Volume Ratio:0.49
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3359
EPS(LYR):-0.3570
ROE:-64.93%
ROA:-25.70%
PB:5.72
PE(LYR):-12.80

Loading ...

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.

Benzinga
·
Nov 04, 2025

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

GlobeNewswire
·
Oct 28, 2025

Taysha Gene Therapies Inc : Raymond James Initiates Coverage With Strong Buy Rating; Price Target $13

THOMSON REUTERS
·
Oct 21, 2025

Taysha Gene Therapies initiated with a Strong Buy at Raymond James

TIPRANKS
·
Oct 21, 2025

Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Oct 20, 2025

Why Is Taysha Gene Therapies Stock Falling Friday?

Benzinga_recent_news
·
Oct 18, 2025

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA), Artiva Biotherapeutics, Inc. (ARTV) and Perspective Therapeutics (CATX)

TIPRANKS
·
Oct 17, 2025

Bank of America Securities Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)

TIPRANKS
·
Oct 17, 2025

Taysha Gene Therapies Price Target Maintained With a $10.00/Share by Needham

Dow Jones
·
Oct 17, 2025

Strategic Advantage and Positive Outlook: Taysha Gene Therapies Maintains Buy Rating

TIPRANKS
·
Oct 17, 2025

Taysha Gene Therapies Inc: Dosing of First Patient in Reveal Pivotal Trial Is Scheduled This Quarter

THOMSON REUTERS
·
Oct 17, 2025

Taysha Gene Therapies Inc - 2022 Option Agreement Between Astellas and Taysha Has Expired

THOMSON REUTERS
·
Oct 17, 2025

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

GlobeNewswire
·
Oct 17, 2025

Taysha Gene Therapies (TSHA): Fresh Rett Syndrome Data Fuels New Discussion on Valuation and Growth Potential

Simply Wall St.
·
Oct 12, 2025

Taysha Gene Therapies price target raised to $9 from $8 at BofA

TIPRANKS
·
Oct 10, 2025

Truist Financial Remains a Buy on Taysha Gene Therapies (TSHA)

TIPRANKS
·
Oct 10, 2025

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

GlobeNewswire
·
Oct 09, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 04, 2025

Taysha Gene Therapies (TSHA) Receives a Buy from Truist Financial

TIPRANKS
·
Oct 03, 2025